The research team, led by investigators at Children’s Hospital, Zhejiang University School of Medicine, together with collaborators spanning thirteen pediatric intensive care units across China, assembled a retrospective cohort of 2,374 children under eighteen years of age who were admitted to intensive care with suspected infections between 2023 and 2025. Rather than treating this population as a single undifferentiated group, the investigators prespecified two clinically distinct sub-cohorts for focused analysis: a neonatal group of 576 infants aged twenty-eight days or younger, and a hematology group of 494 children, a population in which underlying malignancies, immunosuppression, and hematologic abnormalities complicate both the diagnosis of sepsis and the interpretation of laboratory-based severity scores. This design choice reflects a growing recognition in the field that a scoring system validated in a general pediatric intensive care population may not transfer cleanly to the extremes of age or to immunocompromised patients.

Methodologically, the study followed a disciplined approach to score calculation. For each child, both the Phoenix sepsis score and the pSOFA score were computed using the worst available physiological and laboratory values recorded within the first twenty-four hours of intensive care unit admission. This window matters: early severity assessment is precisely what clinicians need when deciding how aggressively to resuscitate, monitor, and escalate care. The primary outcome was in-hospital mortality, and the principal metric of prognostic accuracy was the adjusted area under the receiver operating characteristic curve, or AUROC, a statistic that captures how well a score discriminates between children who died and those who survived, with 0.5 representing chance-level performance and 1.0 representing perfect discrimination. By adjusting the AUROC, the researchers accounted for confounding structure in the data, strengthening the comparability of the two scores.

The headline finding is statistically clear. Across the full cohort of 2,374 critically ill children, the Phoenix sepsis score achieved an adjusted AUROC of 0.840, significantly outperforming the pSOFA score’s 0.817, with a P value below 0.001. In absolute terms the difference may appear modest, but in the world of mortality prediction models, where incremental gains in discrimination can translate into earlier recognition and redirected resources for the sickest patients, such a difference across a cohort of this size carries weight. The result provides external validation, on a scale and in a healthcare context distinct from the original derivation studies, that the Phoenix framework’s emphasis on four organ systems, respiratory, cardiovascular, coagulation, and neurologic, captures lethal trajectories in infected children at least as well as, and slightly better than, the older pSOFA construct.

The picture grows more complicated in the predefined sub-cohorts. In the hematology group, the Phoenix score again outperformed pSOFA, with adjusted AUROCs of 0.718 versus 0.682, a difference that reached statistical significance at P equal to 0.006. Yet the investigators were careful to characterize discriminative ability in this subgroup as limited for both tools. Children with hematologic disease present a notoriously difficult prediction problem: baseline cytopenias, chemotherapy-related organ toxicity, and altered inflammatory responses can all inflate or deflate organ dysfunction scores independent of sepsis severity. A score of 0.718, while better than chance, leaves substantial room for misclassification, and the authors’ framing suggests that neither score should be treated as a reliable standalone prognostic instrument in this vulnerable population.

In neonates, the story changes again. Among the 576 infants aged twenty-eight days or younger, the Phoenix score posted a strikingly high adjusted AUROC of 0.915 compared with 0.850 for pSOFA, but the difference did not reach statistical significance, with P equal to 0.222. The absence of a significant gap does not mean either score performed poorly; indeed, both achieved excellent discrimination in this low-event-rate setting. Rather, the finding suggests that in newborns the two instruments are statistically interchangeable for mortality prediction, an important practical conclusion given that the Phoenix criteria were designed to span pediatric and neonatal populations and that neonatal sepsis has long posed unique challenges, from nonspecific clinical presentation to the scarcity of neonate-specific validation data for adult-derived scoring frameworks.

Beyond discrimination, the study examined how the scores behave at their operational threshold, the cutoff clinicians actually use to flag sepsis. At the standard threshold of two or more points, both the Phoenix score and pSOFA maintained high sensitivity, exceeding 80 percent across all cohorts, meaning they rarely missed a child who went on to die. The trade-off came in specificity: positive predictive values were low, at or below 50 percent everywhere, and in the neonatal sub-cohort they fell below 8 percent. This asymmetry is not a flaw unique to these scores but a mathematical consequence of applying screening thresholds in settings where deaths are, thankfully, uncommon. A highly sensitive tool catches nearly everyone at risk, but in a population where most children survive, most flagged children will nonetheless survive, producing many false alarms.

The trade-off between sensitivity and positive predictive value took on a different character in the hematology sub-cohort, where the event rate was high enough to make predictive values more meaningful. There, the Phoenix score traded approximately five percentage points of sensitivity for a meaningfully higher positive predictive value than pSOFA. In practical terms, the Phoenix score was somewhat more likely to miss a child who died, but when it flagged a child, that flag was more often correct. Which trade-off a clinician or unit should prefer depends on context: in settings where missing a death is the dominant concern, sensitivity may reign; where flagged patients trigger resource-intensive interventions, a higher positive predictive value reduces unnecessary escalations. The study does not prescribe a choice but equips decision-makers with the quantitative texture needed to make one.

The findings land amid an active international debate about the Phoenix criteria, which were developed and validated by a global consensus effort published in JAMA in 2024 and have since undergone external validation in cohorts from the United States, Bolivia, Australia, and beyond, with mixed results in low-resource settings and emergency departments. The new Chinese multicenter analysis adds a critical piece: evidence from a large, geographically diverse, non-Western cohort, with dedicated attention to neonates and hematology patients, two groups underrepresented in earlier validation work. It also complements the research group’s own prior multicenter study of the Phoenix score, pSOFA, and SIRS criteria in non-intensive care settings, extending the comparison to the sickest children in intensive care.

For the field, the message is one of calibrated confidence. The Phoenix sepsis score can now claim superior discrimination for in-hospital mortality in the general population of critically ill children with suspected infection, supporting its adoption in pediatric intensive care contexts. But the study simultaneously cautions against universal enthusiasm: in neonates, the older pSOFA remains an equally defensible choice, and in children with hematologic disease, both scores fall short of what clinicians would want from a decision-support tool, underscoring the need for population-specific approaches, whether through recalibration, integration of novel biomarkers, or entirely new models tailored to immunocompromised hosts. As sepsis mortality prediction moves from one-size-fits-all scores toward precision risk stratification, this study provides both a benchmark and a reminder that the sickest children often defy the averages on which general scores are built.

Subject of Research: External validation comparing the Phoenix sepsis score and pSOFA for predicting in-hospital mortality in critically ill children with suspected infection.

Article Title: Discrimination performance of the Phoenix sepsis score versus pediatric sequential organ failure assessment for predicting in-hospital mortality in critically ill children: a multicenter external validation study

Article References: Ru, X.-W., Liu, R.-Y., Yang, Z.-H., Huang, C.-Z., Zhang, C., Li, T.-W., Yang, J.-M., Liu, Y., Cui, X.-Y., Chen, H.-B., Zhou, X., Tang, F., Gong, X.-Y., Ling, P., Lv, X., Zeng, Q., Ma, Z., Yuan, B.-Y., Zhu, H., … Ye, Q. (2026). Discrimination performance of the Phoenix sepsis score versus pediatric sequential organ failure assessment for predicting in-hospital mortality in critically ill children: a multicenter external validation study. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01073-y

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01073-y

Keywords: Phoenix sepsis score, pSOFA, pediatric sepsis, in-hospital mortality, critical care, neonatal sepsis, hematology, AUROC, external validation, organ dysfunction, predictive scoring, intensive care unit

The case for that shift rests on a fundamental biological reality: sepsis is not one disease. It is a syndrome of dysregulated host responses to infection, and in children this heterogeneity is particularly striking. Different pathogens activate fundamentally different immune cascades, from novel respiratory viruses such as influenza and respiratory syncytial virus to diverse Gram-negative and Gram-positive bacteria and fungi. Layered on top of this pathogen diversity are individual genetic polymorphisms that make each child’s initial response drastically different. Using peripheral blood RNA transcriptomic sequencing, international research teams have identified distinct sepsis response signatures, including the SRS1 and SRS2 endotypes, revealing a highly polarized biological spectrum hiding behind a single clinical label.

The divergence does not stop at molecular signatures. Some patients present early with a hyperinflammatory endotype, the so-called cytokine storm, driving widespread systemic endothelial activation and a surge in vascular permeability. Others, especially neonates or children with underlying immunodeficiencies, rapidly slide into the opposite state: a hypoinflammatory or immunoparalyzed endotype characterized by leukocyte reprogramming and global mitochondrial bioenergetic failure. Big data approaches and unsupervised machine learning algorithms such as latent class analysis have confirmed that pediatric sepsis comprises distinctly different severe sub-phenotypes, including shock-dominant forms, multiorgan dysfunction syndrome, and hyperferritinemic or macrophage activation-like syndromes. Two children with identical sepsis diagnoses may therefore harbor completely antithetical underlying host responses and mechanisms of injury.

Meanwhile, the way acute kidney injury itself is diagnosed is under intense scrutiny. For decades, staging has relied almost entirely on the Kidney Disease: Improving Global Outcomes criteria, based on elevated serum creatinine and decreased urine output. But these are crude functional filtration markers that lack microstructural pathological granularity. In pediatric critical care, baseline creatinine varies widely by age, developmental stage, sex, and muscle mass, and it rises with a significant physiological lag after renal injury. Early fluid resuscitation compounds the problem: pathological fluid accumulation and fluid overload dilute serum creatinine, frequently masking or delaying a timely diagnosis. Static urine output assessments, the editorial notes, fail to integrate mass balance and the actual fluid dynamics of the patient. Notably, the newly published KDIGO 2026 draft guidelines explicitly advocate incorporating novel structural and stress biomarkers alongside traditional functional metrics to redefine acute kidney injury and recognize subclinical structural damage before function declines.

The kidney itself is far from a uniform organ. Anatomically it is divided into cortex, outer medulla, and inner medulla, each with radically different vulnerabilities. The cortex receives abundant blood flow and drives filtration, whereas the medulla receives less than ten percent of total renal blood flow, and its specialized vasa recta countercurrent multiplier system leaves it naturally on the brink of hypoxia. In sepsis, systemic hemodynamic redistribution often produces severe, occult hypoxia in the renal medulla that standard monitoring never sees. The organ contains more than thirty distinct cell types, including glomerular endothelial cells, podocytes, and proximal and distal tubular epithelial cells, each reacting uniquely to circulating inflammatory cytokines, endotoxins, and damage-associated molecular patterns. The proximal tubule, particularly the S3 segment, is highly metabolically active and dependent on mitochondrial oxidative phosphorylation, making it the epicenter of structural damage.

Single-cell technologies have pushed this anatomical insight to a molecular level. Single-cell RNA sequencing shows that metabolically active proximal tubular cells and distinct nephron segments, such as the loop of Henle, follow divergent gene reprogramming and injury pathways during sepsis. Critically, two pediatric patients meeting identical KDIGO stage 3 criteria may harbor diametrically opposed internal microenvironments. One may experience a transient, functional alteration driven by relative volume deficit, rapidly reversible with titrated fluid resuscitation. The other may suffer persistent, damage-associated injury marked by acute tubular necrosis, severe microvascular endothelial barrier disruption, and widespread apoptosis. Expanding on initial adult cohorts, recent pediatric critical care research has validated distinct biological sub-phenotypes of acute kidney injury in critically ill children, including low-inflammatory/mild injury and hyperinflammatory/endothelial injury groups, whose clinical trajectories, renal recovery probabilities, and long-term mortality risks are fundamentally disparate.

When systemic sepsis heterogeneity intersects with organ-level microenvironmental heterogeneity, the kidney becomes both a passive target of the immune storm and an active amplifier of inflammation and microcirculatory breakdown. Modern pathophysiological research shows that hyperinflammatory sepsis triggers widespread shedding and degradation of the vascular endothelial glycocalyx, the protective sugar-rich coating of blood vessels. Stripped of this layer, the microvascular endothelium exposes adhesion molecules, prompting neutrophils and platelets to aggregate, adhere, and roll along renal microvascular walls, producing severe spatial mismatching of capillary blood flow and localized microthrombi. This explains the dissociation between macrocirculation and microcirculatory tissue perfusion: even when systemic blood pressure is normalized and total renal blood flow preserved or increased, local renal microvessels remain trapped in severe, occult tissue hypoxia. To survive, tubular epithelial cells initiate gene reprogramming and metabolic downregulation, entering a protective, cell-cycle-arrested quiescent state.

This structure-function mismatch, the authors argue, is precisely why past large-scale trials in sepsis-associated kidney injury overwhelmingly failed: interventions were applied uniformly across broad clinical syndromes, ignoring the distinct biological sub-phenotypes of individual patients. To break the deadlock, recent international consensus reports, including the 23rd and 28th Acute Disease Quality Initiative workgroup statements, advocate transforming static functional diagnoses into a dynamic theragnosis framework built on predictive enrichment. The diagnostic core is a multimodal biomarker matrix. Structural injury markers such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) enable detection of subclinical stage 1S injury before creatinine rises, allowing clear stratification of functional versus damage-associated injury. Cell-cycle arrest markers, specifically the product of urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 (TIMP-2 × IGFBP-7), and tubular stress indicators like urinary Dickkopf-3 provide early warning of children progressing toward irreversible tubular damage. Simultaneously profiling systemic biomarkers, including interleukin-6, chemokines, soluble thrombomodulin, angiopoietin-2, and olfactomedin-4, allows clinicians to map whether a patient carries a hyperinflammatory/endothelial-disruption endotype or a hypoinflammatory/energy-suppressed one.

Treatment, in turn, must be tailored to phenotype, because directed interventions show profound heterogeneity of effect across pediatric sub-phenotypes. The editorial, grounded in the landmark AKI1 (low-inflammatory/mild injury) and AKI2 (high-inflammatory/severe endothelial injury) sub-phenotype framework updated with pediatric evidence, maps dichotomous, phenotype-driven intervention strategies. Looking ahead, the authors call for a tripartite synergy: artificial intelligence-driven clinical decision support systems that integrate bedside point-of-care biomarker testing with electronic health record algorithms, such as an automated renal angina index paired with a secondary urinary NGAL tiering pathway; refined clinical trial endpoints that abandon renal replacement therapy initiation as an indiscriminate endpoint in favor of biologically aligned benchmarks such as RRT-free survival days, AKI duration, and fluid-balance-related organ damage; and adaptive platform and umbrella trial designs that introduce transcriptomic endotypes and segment-specific urinary biomarkers into multicenter research. By abandoning the one-size-fits-all approach, the editorial concludes, clinicians can build a precise diagnostic framework bridging systemic host responses and local renal microenvironments, ultimately rewriting the long-term renal outcomes and survival trajectories of every critically ill child with sepsis.

Subject of Research: Precision medicine approaches for pediatric sepsis-associated acute kidney injury based on systemic and organ-level heterogeneity

Article Title: Precision medicine in pediatric sepsis-associated acute kidney injury: when systemic heterogeneity meets organ-level heterogeneity

Article References: Wu, M.-Y., Zhao, Y., Chen, X.-H., & Ge, X.-H. (2026). Precision medicine in pediatric sepsis-associated acute kidney injury: when systemic heterogeneity meets organ-level heterogeneity. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01096-5

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01096-5

Keywords: pediatric sepsis, acute kidney injury, precision medicine, biomarkers, sub-phenotypes, serum creatinine, KDIGO guidelines, single-cell RNA sequencing, endothelial glycocalyx, machine learning, renal angina index, intensive care